VISCHER has advised Royalty Pharma Investments. Mintz and Schellenberg Wittmer have advised Neurimmune AG. Royalty Pharma Investments has acquired a portion of Neurimmune AG’s royalty interest...
Royalty Pharma Acquires Royalty Interest in Cliramitug from Neurimmune
FimmCyte and Gedeon Richter Enter Strategic Research Collaboration in Endometriosis Therapies
VISCHER has advised FimmCyte. FimmCyte AG, a Swiss biotechnology company, has established a strategic research collaboration and option-to-license agreement with Gedeon Richter Plc., a major Hungarian...
Oncobit and ID Solutions Form Strategic Oncology Diagnostics Partnership
VISCHER has advised Oncobit. Oncobit, a Swiss company specializing in precision oncology, has entered into a strategic partnership with ID Solutions, a French developer of innovative...
FoRx Therapeutics Secures USD 50 Million in Series A Financing to Advance Phase 1 Clinical Development
VISCHER has advised FoRx Therapeutics AG. FoRx Therapeutics AG, a clinical-stage biotechnology company, has completed a USD 50 million Series A financing round. The funding round...
Aukera Therapeutics Secures CHF 4.5 Million in Funding and Expands Board
VISCHER has advised Aukera Therapeutics. Aukera Therapeutics, a preclinical-stage biotech spin-off from the University of Basel, has raised approximately CHF 4.5 million in funding and announced...
Proteomedix AG Licenses Manufacturing IP for Cancer Diagnostic to Immunovia AB
VISCHER has advised Proteomedix AG on its licensing agreement with Immunovia AB. Proteomedix AG, a Swiss biotech subsidiary of Onconetix, Inc., has entered into a licensing...
Medartis Acquires Full Ownership of KeriMedical
VISCHER has advised Medartis. McDermott has advised KeriMedical. Medartis, a Basel-based orthopedic company listed on the SIX Swiss Exchange, has acquired the remaining 53% stake in...
AutoScout24 Integrates C2B Auction Platform from CARAUKTION
VISCHER has advised CARAUKTION. AutoScout24 has completed the acquisition of the consumer-to-business (C2B) segment previously developed in partnership with CARAUKTION, including the C2B auction platform. Effective...
HAYA Therapeutics SA’s $65 Million Series A Funding Round
Lenz & Staehelin acted for Eli Lilly; Kellerhals Carrard advised Sofinnova Partners and Earlybird Venture Capital; VISCHER acted for HAYA Therapeutics AG. Wilson Sonsini Goodrich &...
Granite Bio AG’s $100 Million Funding Round
VISCHER advised Forbion and Sanofi Ventures on all legal issues related to the transaction. Granite Bio AG, a clinical-stage immunology company developing first-in-class antibodies that target...
ImmunOs Therapeutics AG’s $11 Million Series C Financing Round
VISCHER advised ImmunOs Therapeutics AG on all legal issues related to the transaction. ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its unique immune system modulating HLA-based...
HAYA Therapeutics SA’s Collaboration Agreement With Eli Lilly
VISCHER advised Haya Therapeutics SA on the Swiss legal aspects of the transaction. Cooley acted as lead counsel in this transaction. HAYA Therapeutics SA, a Swiss...